Breaking Finance News

UBS Securities announced Abbvie Inc (NYSE:ABBV), raising its target price to $9.00 today

Abbvie Inc (NYSE:ABBV) had its target bumped up to $9.00 by UBS Securities in an issued report issued 10/13/2017. The upped price target suggests a potential downside of -0.90% from the company's last closing price.

On Thursday October 05, 2017, Leerink Swann reported about Abbvie Inc (NYSE:ABBV) raised the target price from $0.00 to $10.00 that suggested a downside of -0.89%.

Having a price of $90.84, Abbvie Inc (NYSE:ABBV) traded -0.67% lower on the day. The last closing price is up 24.94% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time. The company has recorded a 50-day moving average of $84.59 and a 200-day moving average of $72.69. Trade Volume was down over the average, with 4,179,969 shares of ABBV changing hands under the typical 6,227,120

Recent Performance Chart

Abbvie Inc (NYSE:ABBV)

Abbvie Inc has a price-earnings ratio of 22.33 with a 52 week low of $55.06 and a 52 week high of $92.61 The company’s market cap is currently $0.

In addition to UBS Securities reporting its stock price target, a total of 18 brokerages have issued a ratings update on Abbvie Inc. The 12-month price target is $70.22 with 4 firms rating the stock a strong buy, 10 brokers rating the stock a buy, 5 brokers rating the stock a hold, one equity analyst rating the company a underperform, and lastly zero analysts rating the company a sell.

General Company Details For Abbvie Inc (NYSE:ABBV)

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.